AIM Immunotech gains on research deal for cancer drug study

AIM ImmunoTech

17/01/2023 14:55

** Shares of drug developer AIM Immunotech  AIM.A  rise ~15%
to 72 cents in early trading 
    ** Co says has entered into collaborative clinical research
agreement with Erasmus Medical Center and drugmaker AstraZeneca
 AZN.L  
    ** Under the deal, Erasmus Medical Center will conduct a
clinical trial to evaluate a combination of AIM's drug Ampligen
and AstraZeneca's  AZN.L  immunotherapy durvalumab as a
potential treatment for metatastic pancreatic cancer
    ** Co is also separately evaluating Ampligen as a potential
treatment for advanced pancreatic cancer in a mid-stage study  
    ** Up to last close, AIM has fallen ~31% in the last 12
months 
 (Reporting by Bhanvi Satija in Bengaluru)
 ((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91
9873062788;))